Karyopharm lays off 20% of staff to focus cash on Xpovio cancer trials
Karyopharm Therapeutics announced it is laying off about 20% of its staff and amended a financing agreement in order to stretch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
